Allarity Therapeutics Secures US Patent Allowance for Stenoparib DRP® Companion Diagnostic
ALLR sits 78% above its 52-week low of $0.769.
Summary
Allarity Therapeutics received a Notice of Allowance from the USPTO for its DRP® companion diagnostic for stenoparib, securing US market exclusivity until at least 2039 for its lead cancer drug.
Key Events · Product Development and Regulatory · ALLR
-
US Patent Allowance Received
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Allarity Therapeutics' patent application covering its DRP® companion diagnostic specific to stenoparib.
-
Extended Market Exclusivity
The patent, expected to be formally granted within three months, would provide market exclusivity in the US at least into 2039 for stenoparib when used in concert with the DRP® diagnostic.
-
Strengthens Lead Asset
This intellectual property protection is a major step in expanding and protecting the commercial potential of stenoparib, the company's lead asset currently in Phase 2 clinical trials for ovarian and other cancers.
Analysis · ALLR · Life Sciences
This 8-K announces a significant intellectual property milestone for Allarity Therapeutics, with the USPTO issuing a Notice of Allowance for its DRP® companion diagnostic for stenoparib. This patent, expected to be granted within three months, will provide market exclusivity in the US until at least 2039 for stenoparib when used with the diagnostic. This strengthens the commercial potential and competitive position of their lead asset, stenoparib, which is in Phase 2 trials for ovarian and other cancers. It builds on the company's strategic focus on stenoparib and recent positive scientific presentations, significantly de-risking its future commercialization.
At the time of this filing, ALLR was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.7M. The 52-week trading range was $0.77 to $2.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.